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Possible novel targets for therapeutic angiogenesis
Brunella Cristofaro and Costanza EmanueliAn increasing number of studies about the molecular basis of
angiogenesis are rapidly disclosing novel signal pathways
involved in the blood vessel formation process. This review will
focus on bone morphogenic proteins, Hedgehog, Notch,
ephrins, neuropilins, neurotrophins and netrins. These recently
discovered angiogenesis mediators are involved in vascular
development during embryogenesis and, interestingly, they are
shared between the nervous and vascular systems. They
represent new potential targets in the vasculature and suggest
novel therapeutic opportunities.Address
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Introduction
The concept of therapeutic angiogenesis evolved from
pioneering work by Folkman, who documented the
dependency of cancer growth upon neovascularization
and suggested the existence of proangiogenic growth
factors (GFs) [1]. The first identified proangiogenic
GFs, which belong to the families of vascular endothelial
growth factors (VEGF) and fibroblast growth factors
(FGFs), were soon exploited by cardiovascular scientists
to test the hypothesis that stimulating angiogenesis by
therapeutically overexpressing GFs could improve per-
fusion and function in ischaemic situations, including
limb ischaemia, myocardial infarct and cutaneous ulcers
[2]. A large number of vascular GFs have now been
identified. This article aims to give an overview on
recently described angiogenic pathways, most of which
were initially identified in embryonic vascular develop-
ment and differentiation. Interestingly, these pathways
impact on the development, survival and regeneration of
both the vascular and nervous systems. Therefore, their
pleiotropic capacity makes them interesting therapeutic
targets.
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BMPs belong to the transforming growth factor (TGF)-
superfamily and signal through cell surface complexes of
type I and type II serine/threonine kinase receptors. Once
activated, these kinases form heterodimers and mediate
intracellular signaling through Smad proteins. BMP
activity is modulated by extracellular binding proteins,
such as BMPER (BMP endothelial cell precursor-derived
regulator) and noggin.
BMPs were initially described to induce ectopic bone
formation and control axis development and organogen-
esis during embryogenesis [3]. Recent evidence high-
lights the central role of BMPs in vascular
development. Several BMPs have been identified in
mammals. BMP2/BMP4 group appears the most import-
ant for cardiovascular development. BMP4/ mouse
embryos die mostly around ED7.5 with defects in meso-
derm formation and patterning. The few surviving
embryos die at ED9.5 (time of vascular formation) and
display a vascular phenotype with a reduced number of
blood islands. These observations suggest that BMP4 is
necessary for endothelial progenitor cell (EPC) differen-
tiation [4]. Knocking out either Smad5 or Smad1 results in
embryonic death around midgestation, due to several
vascular defects [5–7]. BMPs are also involved in post-
natal neovascularization. BMP4, via BMPER interaction,
induces in vitro migration of endothelial cells (EC) and
increases capillary network density in the in vivo chick
embryo chorioallantoic membrane (CAM) and matrigel
plug assays [8]. BMP4-induced angiogenesis is mediated
by ERK1/2 [9]. BMP2/4 may also be involved in vascu-
logenesis. In fact, Smadja et al. documented that BMP2/4
stimulates proliferation, migration and tube formation
capacities of endothelial colony-forming cells (ECFCs),
a bone marrow (BM)-derived population with a strong
vessel-forming potential. Moreover, BMPs are required
for human progenitor cell commitment to the endothelial
lineage. Also, noggin (BMP endogenous antagonist) sig-
nificantly attenuated ECFCs growth from mononuclear
cell cultures [10].
Hedgehog (Hh)
Hh family was originally identified in Drosophila as a
crucial regulator of cell-fate determination during embry-
ogenesis. Hh members act as morphogens by regulating
epithelial–mesenchymal interactions essential to limb,
lung, gut, hair follicles and bone formation. There are
three homologues of the Drosophila Hh genes in mam-
mals: Sonic hedgehog (Shh), Desert hedgehog (Dhh) and
Indian hedgehog (Ihh). Among them, Shh is the most
widely expressed during development and Shh deficiencywww.sciencedirect.com
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and mid gestation [11,12]. Ihh is not so broadly expressed
and Ihh/ mice survive until late gestation [13,14]. Dhh
is expressed in the peripheral nerves, male gonads and
EC of large vessels during development. Dhh/mice are
viable, but display peripheral-nerve and male-fertility
defects [15]. Hhs signal through interaction with the
Patched-1 (Ptc1) receptor, which activates transcriptional
factors belonging to Gli family.
Several evidences suggested the participation of Hhs in
vascular development. Shh/ zebrafishes reveal disor-
ganization of EC precursors and lack to form the dorsal
aorta or axial vein. Shh/ mice display an abnormal
vascularization in developing lung. Conversely, trans-
genic Shh overexpression in the dorsal neural tube in
mice induces hypervascularization of neuroectoderm
[16]. Shh is required for arterial differentiation. Shh/
zebrafish embryos fail to express ephrin-B2a within their
vasculature, while exogenous Shh induces ectopic for-
mation of arteries by promoting VEGF expression [16].
Pola et al. showed that recombinant Shh promotes a robust
neovascularization in ischaemic hindlimbs. Shh-induced
angiogenesis is characterized by large-caliber vessels and
is mediated by fibroblasts producing a combination of
potent angiogenic factors (VEGF, Angiopoietins) [17]. By
contrast, Shh inhibition downregulates VEGF and
impairs post-ischaemic angiogenesis [18]. In mice with
myocardial infarction (MI), Shh gene transfer upregulated
VEGF, Angiopoietins, IGF-1 and SDF-1 and promoted
neovascularization, partially by enhancing the recruit-
ment of BM-derived EPCs in the infarcted area [19].
Finally, Shh reportedly mitigated diabetic neuropathy by
increasing the number of both epineural/perineural and
endoneural capillaries and thus improving nerve blood
flow in rats [20].
Notch
Notch signaling is a highly conserved pathway, impli-
cated in cell-fate decisions and differentiation of epi-
thelial, neuronal, bone, blood, muscle and EC. In
mammals, four Notch receptors (1–4) have been
described. Notch receptors interact with transmembrane
ligands expressed on neighbour cells. Notch ligands are
encoded by the Jagged (Jag1 and Jag2) and Delta-like
(Dll11, Dll3 and Dll4) gene families. Ligand binding
induces gamma-secretase-mediated Notch cleavage and
the subsequent translocation of the Notch intracellular
domain (NICD) in the nucleus, where it interacts with
RBP-J proteins to function as a transcription factor for
downstream target genes, including that of the Hes/Hey
family.
The contribution of Notch to vascular biology has been
appreciated only recently. Notch1 and Notch4 are pre-
dominant in EC, whereas Notch1 and Notch3 are present
in vascular smooth muscle cells (VSMC). Of the fivewww.sciencedirect.comligands, Dll1, Dll4 and Jag1 are prevalently expressed
in EC, while Jag1 and Jag2 and, to some degree Dll1, are
also found in VSMC.
Mutations in Notch signaling alter vascular development,
at multiple steps and to various degrees. Loss-of-function
studies documented the importance of Notch at the stage
of vascular remodelling, when the primitive plexus
evolves into a hierarchic network. Notch1/ murine
embryos die by ED9.5 with defects in somitogenesis
and severe cardiovascular anomalies [21,22]. Endo-
thelium-specific Notch deletion is lethal at ED10.5, dis-
playing profound vascular abnormalities in placenta, yolk
sac and embryo [23].Notch3/mice are viable and fertile,
but they show enlarged arteries with abnormal distri-
bution of elastic laminae, suggesting the importance of
Notch3 for the differentiation and acquisition of VSMC
arterial identity [24]. Notch4 inactivation did not generate
observable vascular defects. However, Notch1/Notch4
double knockout mice exhibit a more severe vascular
phenotype than Notch1/, indicating that Notch1 and
Notch4 may have overlapping roles in vascular remodel-
ling and morphogenesis during development [22]. Dll4/
 embryos die at E9.5. Similar to Notch1/, they fail to
properly remodel the primitive vascular plexus. In
addition, their phenotype has other similarities with
Notch1/, including stenosis of the large arteries and
defective arterial branching [25–27]. Jag1/ mice die
by E10.5, failing to remodel the primary vascular plexus
to form the large vitelline blood vessels, a process that
normally occurs by angiogenesis.
Several studies document a primary function of Notch
signaling in regulating arteriovenous differentiation of
EC during vascular development. Notch signaling-
deficient zebrafish embryos exhibited a loss of expression
of arterial markers from arterial vessels with an accom-
panying expansion of venous markers into normally arter-
ial domains. Zebrafish embryos in which Notch signaling
had been ectopically activated presented the reverse
phenotype: suppression of vein-specific markers with
ectopic expression of arterial markers in venous vessels
[28]. Mutations in Notch members are responsible for
certain late-onset hereditary vascular anomalies in
humans. Alagille syndrome (AGS) is an autosomal domi-
nant disorder that has been attributed to Jag1 mutations.
AGS patients exhibit abnormal blood vessels, arterial
stenosis and heart disease, in addition to hepatic lesions
and skeletal defects [29]. CADASIL is a disease charac-
terized by strokes, migraines and progressive dementia. It
has been linked to a Notch3 mutation, resulting in pro-
gressive degeneration of the VSMC layer surrounding
cerebral and skin arterioles [30,31].
A crucial role of Notch has also been demonstrated in
postnatal angiogenesis. EC-selective Notch1 deletion
impairs post-ischaemic angiogenesis in limb muscles.Current Opinion in Pharmacology 2009, 9:102–108
104 Cardiovascular and renalIn this model, Notch1 angiogenic action is regulated by
VEGF, as VEGF, via Akt, increases presenilin proteolytic
processing, gamma-secretase activity, Notch1 cleavage
and Hes1 expression in EC [32].
Ephrins and Eph receptors
The ephrin ligand/Eph receptor family is widely
expressed in embryonic and adult tissues. Its functions
are best characterized in the nervous system, where it is
involved in patterning the developing hindbrain rhom-
bomeres, axon pathfinding and guiding neural crest cell
migration [33].
Eph receptors are tyrosine kinases, divided in two sub-
classes, A (EphA) and B (EphB), depending on the type of
interaction with the epharin ligands. In general, EphA
bind to GPI anchored ephrin ligands (ephrin-A), while
EphB bind to ephrin ligands containing transmembrane
domains (ephrin-B) [34]. Ephrin–Eph-mediated signaling
functions bidirectionally; after cell contact-mediated
binding of the ligand, the Eph tyrosine kinases become
clustered and phosphorylated, which leads to recruitment
of signaling effectors and activation of signal-transduction
cascades.
The involvement of ephrin–Eph molecules in vascular
development is considerable. In fact, they have an essen-
tial role in the maturation and remodelling of the arterial–
venous plexus. Ephrin-B2 expression specifically in the
arterial and EphB4 in the venous endothelium represent
one of the earliest known molecular distinctions between
arteries and veins. Disruption of either gene leads to
failure in the remodelling of the primary capillary plexus
and in the formation of major embryonic vessels [35–37].
Interaction between ephrin-B2 and EphB4 at the arterial–
venous interface is required to provide repulsion signals
for the establishment and maintenance of boundaries
between these vessels [35,37]. Furthermore, ephrin/
Eph interaction between mesenchymal cells and EC
mediates repulsive guidance for migrating EC during
the formation of intersomitic vessels [37,38]. In vitro
studies support the angiogenic nature of ephB/ephrin-B
signaling. In cultured microvascular EC, EphB4 acti-
vation by ephrin-B2 triggers sprout formation as effi-
ciently as VEGF or angiopoietin-1 [37]. Moreover,
ephrin-B2 expression in cultured human microvascular
ECs and arterial ECs can be induced by VEGF, bFGF
and HGF (hepatocyte GF) [39].
The role of Ephrins/Eph receptors in therapeutic angio-
genesis has been only partially explored. EphrB2 expres-
sion is higher at the site of reparative neovascularization
in murine ischaemic muscles [40]. Importantly, intraper-
itoneal administration of ephrin-B2 in MI mice enhanced
EC proliferation and increased capillary density in the
periinfarcted area [40]. Moreover, EphB4 activation, via
an ephrin-B2–Fc chimeric protein, enhanced the proan-Current Opinion in Pharmacology 2009, 9:102–108giogenic capacity of EPC in a mouse model of hindlimb
ischaemia. In fact, ischaemic nude mice undergone
ephrin-B2–Fc-treated EPC injection displayed increased
capillary and vessel densities as well as improvement in
blood flow recovery compared with the untreated mice
[41].
Neuropilins (NRP)
NRP-1 and NRP-2 are transmembrane proteins initially
identified as receptors for class-3 semaphorin subfamily.
They are involved in neuronal cell guidance and axonal
growth during development of the nervous system, exert-
ing a repulsive/inhibitory effect on neuronal growth
cones. Neuropilins are also involved in angiogenesis
and cardiovascular functions and they can bind to certain
isoforms of VEGF. These observations place the NRPs at
the heart of the cross-talk between the nervous and the
vascular systems.
Both NRP1 and NRP2 are expressed in EC [42,43],
where NRP1 enhances VEGF165 binding to VEGF re-
ceptor 2 (VEGFR2), thus improving EC migration [44].
By contrast, sema3A inhibits VEGF-induced EC
migration and sprout formation due to competition with
VEGF165 for binding to NRP1 [45]. NRP null mutation is
lethal in mice. NRP/ embryos presented severe
neuronal alterations as well as deficiencies in neuronal
vascularization, aortic arch malformations and diminished
and disorganized yolk sac vascularization [46]. By con-
trast, NRP1 trasngenic murine embryos showed hyperca-
pillary formation, dilated blood vessels, haemorrhage and
malformed hearts and limbs [42]. NRP2/ mice are
viable, with normal development of larger blood vessels,
but displaying a severe reduction of small lymphatic
vessels and capillaries [47]. Double NRP1//NRP2/
mice had a more severe vascular phenotype than each
single knockout. They died very early in utero and
exhibited defective blood vessel development, including
a lack of blood vessel branching in yolk sacs, failure in
capillary formation and avascular embryos [48].
Little is known about the effect of Neuropilins in thera-
peutic angiogenesis. An in vivo study reported that newly
formed vessels in healing dermal wounds abundantly
express NRP1 and that mice treated with anti-neuropi-
lin-1 antibodies exhibit a decrease in vascular density
within these wounds. In vitro, VEGF-induced cord for-
mation and EC migration was inhibited by antibodies
directed against NRP1 [49]. Additional investigations are
necessary to fully understand Neuropilins potential for
therapeutic angiogenesis.
Neurotrophins (NTs)
NTs are a family of highly conserved proteins consisting
of four different members: nerve growth factor (NGF),
brain-derived neurotrophic factor (BDNF), NT-3 and
NT-4/5. NTs actions are mediated via binding to twowww.sciencedirect.com
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and trkC), which are tyrosin-kinases, and p75NTR, a mem-
ber of the TNF receptor family. Trk receptors exhibit
ligand specificity with NGF binding to trkA, BDNF and
NT 4/5 to trkB and NT-3 to trkC. Conversely, p75NTR
binds all mature NTs with equal but low affinity, while it
hashigher affinity forpro-NTs [49,50].NTsarebestknown
for their actions on the nervous system [51]. Nevertheless,
EC constitutively express trks and respond to NTs with
improved survival, proliferationandmigration [52]. Studies
performed on genetically modified mice underlined the
importance of NTs/trk signaling for cardiovascular devel-
opment. BDNF/ mice exhibited impaired EC survival
and EC cell to cell contacts in intramyocardial arteries and
capillaries, leading to intraventricular wall haemorrhage,
depressed cardiac contractility and early postnatal death
[53]. NT-3/ mice showed defective great vessels and
developmental delay in the primitive myofibril organiz-
ation of the truncus arteriosus [54,55]. Transgenic mice
overexpressing a truncated trkC receptor acting as a domi-
nant negative displayed similar cardiovascular defects [56].
NTs exert potent effects on postnatal angiogenesis.
NGF, by promoting EC proliferation, induces angiogen-
esis in both the cornea pocket [57] and the CAM assays
[58]. The potential of NTs for therapeutic angiogenesis
was demonstrated for the first time by our group using
recombinant NGF in a mouse model of limb ischaemia.
Repeated NGF injections in the ischaemic adductors
reduced EC apoptosis, increased capillary and arteriole
densities and improved blood flow recovery [59,60].
Furthermore, NGF supplementation stimulates thera-
peutic angiogenesis in diabetic cutaneous wounds, thus
promoting cicatrization [61]. NGF-induced angiogenesis
is mediated by the VEGF-Akt-eNOS signaling and
MMP-2 upregulation [59,62,63]. Importantly, both
NGF and trkA are upregulated by limb ischaemia to
mediate the native angiogenesis response, as demon-
strated by the anti-angiogenic effect of a NGF blocking
antibody in this condition [59].
BDNF shares some angiogenic properties with NGF.
BDNF is expressed in EC [62] and its expression is
upregulated by hypoxia as well as limb ischaemia
[64,65,66] Endogenous BDNF promotes EC survival,
whereas exogenously added recombinant protein stimu-
lates in vitro angiogenesis, via VEGF/PI3K/Akt cascade
[65]. BDNF gene transfer promoted blood flow recovery
and increased capillary density in the mouse limb ischae-
mia model. Moreover BDNF overexpression promoted
mobilization of BM-derived CD11b+ myeloid cells and
haematopoietic Sca-1+ precursor cells, which express the
trkB, thus suggesting that BDNF may contribute to
vessel formation by vasculogenesis [64]. Healthy capil-
lary EC do not express p75NTR, but receptor expression is
induced by diabetes and ischaemia [60]. p75NTR expres-
sion promotes EC apoptosis and inhibits the angiogenesiswww.sciencedirect.comprocess [67]. We proved that p75NTR inhibition by local
gene transfer of a dominant negative form of the receptor
can be used therapeutically to restore proper reparative
neovascularization in limb muscle following ischaemia in
diabetic mice [67].
Netrins
Netrins constitute a family of highly conserved secreted
proteins structurally related to laminins. In mammals this
family comprises three members, Netrin-1, Netrin-3 and
Netrin-4. Netrins are bifunctional guidance cues in the
developing central nervous system, attracting some
axons, while repelling others. Attraction and repulsion
are mediated by binding to receptors of the deleted in
colorectal cancer (DCC) and uncoordinated five (UNC5)
families. TheDCC family consists of DCC and neogenin,
while the UNC5 family comprises four members,
UNC5A to UNC5D. Axon attraction is mediated by
the DCC receptors, whereas repulsion requires signaling
through the UNC5 receptor homodimers or with UNC5–
DCC receptor heterodimers [68–71]. Netrins and recep-
tors are expressed in several non-neural tissues, including
EC, thus suggesting a broader role of these molecules in
processes other than axon pathfinding.
The role of Netrins in the developing vascular system is
uncertain, with numerous data reporting both pro-angio-
genic and anti-angiogenic activities. Lu et al. showed that
Netrin-1 is a negative regulator of capillary branching,
acting via UNC5B. UNC5B is localized in developing
blood vessels, and Unc5B/ mice exhibit excessive
branching at this level and excessive extension of filopodia
in endothelial tip cells. Treatment of endothelial tip cells
with Netrin-1 induces filopodia retraction in wild-type
mice but not in Unc5b/ mice, suggesting that Netrin-1
inhibition of vessel branching is mediated by UNC5B.
Furthermore, knockdown of the netrin-1 orthologue in
zebrafish generates abnormal branching in developing
blood vessels [72]. By contrast, other studies suggested a
pro-migratory and pro-mitogenic effect of Netrin-1 on
primary EC and VSMC. According to Park et al., Netrin-
1 stimulates migration and proliferation of both EC and
VSMC. Neogenin was found responsible for the effect in
VSMC but not in EC, where DCC, UNC5 or Neogenin were
not detected.Moreover, Netrin-1-induced angiogenesis in
both the CAM and corneal micropocket assays [73].
Furthermore, Nguyen et al. found that Netrin-1 enhanced
arterial EC proliferation and migration, through a DCC-
dependent increase in nitric oxide production and the
feed-forward activation of ERK1/2–eNOS, [74]. Likewise,
Wilson et al. reported that gene transfer with Netrin-1 and
Netrin-4 facilitates post-ischaemic limb revascularization
via an unknown Netrin receptor [75].
Conclusions
This review tried to focus on some newly revealed
families involved in the angiogenesis process. TheseCurrent Opinion in Pharmacology 2009, 9:102–108
106 Cardiovascular and renalsignaling pathways shape embryonic vascular develop-
ment and are recapitulated in adult tissue, where they
have a regulatory role on reparative angiogenesis. Inter-
estingly, these pathways are shared between the nervous
system and the vasculature. The two systems have much
more in common than was originally anticipated. Indeed,
as we have reported in this article, they use similar signals
and principles to differentiate, grow and navigate towards
their targets. Further investigations on these molecular
mechanisms and their interconnections might give
further hints for new approaches in therapeutic angiogen-
esis.
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